Wen Xue, PhD

Research Focus - CRISPR-Cas Genome Development of Cancer Models

Representative Publications

• AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway. Liang SQ, Walkey CJ, Martinez AE, Su Q, Dickinson ME, Wang D, Lagor WR, Heaney JD, Gao G, Xue W.Mol Ther. 2021 Oct 23:S1525-0016(21)00530-X. doi: 10.1016/j.ymthe.2021.10.023. Online ahead of print.PMID: 34695545 Read Publication

In the News

• 

  Sep 23, 2016

  Wen Xue receives $250,000 for pediatric cancer research from Hyundai Hope on Wheels

  UMass Medical School cancer researcher Wen Xue, PhD, accepted a $250,000 grant Friday from the Hyundai Motor America Hope on Wheels campaign to continue his work toward improving care and treatment options for children with cancer.

  Read more

  , Cancer Center, Wen Xue, Liver Cancer,
• 

  Feb 1, 2016

  CRISPR/Cas9 therapeutic for Tyrosinemia type I delivered to mice

  According to a study published in Nature Biotechnology, a more efficient delivery of a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I developed by Wen Xue, PhD, may also prove to be safer for use in humans.

  Read more

  , Cancer Center, Wen Xue, Liver Cancer,
• 

  Jun 4, 2020

  MD/PhD-student-led research finds potential new gene target for pediatric liver cancer

  A new study by a team of UMass Medical School researchers, led by Jordan Smith, MD/PhD candidate, has identified a new therapeutic target in hepatoblastoma, a rare, primarily pediatric liver cancer.

  Read more

  , School of Medicine, Cancer Center, Faculty, Student, MD/PhD, Wen Xue, Liver Cancer, Biochemistry and Molecular Biotechnology, RNA Therapeutics Institute, Pediatric Hematology/Oncology,
• 

  Nov 18, 2021

  Flotte lab to develop gene therapy models for genetic lung disease

  Researchers from UMass Chan Medical School have received a five-year $13.6 million program project grant from the National Heart, Lung and Blood Institute to develop new gene therapy models for alpha-1 antitrypsin deficiency, a chronic, debilitating genetic lung disease that shortens the lifespan.

  Read more

  , Graduate School of Biomedical Sciences, School of Medicine, Faculty, Rare Disease, Terence Flotte, gene therapy, Guangping Gao, Wen Xue, Flotte Lab, Wang Lab, Dan Wang, Pediatrics, RNA Therapeutics Institute, Li Weibo Institute for Rare Diseases Research, Gruntman Lab, Microbiology and Physiological Systems,
• 

  Mar 5, 2024

  UMass Chan studies selected for STAT Madness

  STAT News has selected three research teams from UMass Chan to compete in its 2024 STAT Madness competition. Members of the public are invited to vote for the best biomedical research from 2023. The first round of voting, which will narrow the field from 64 to 32, has begun.

  Read more

  , Graduate School of Biomedical Sciences, School of Medicine, Faculty, Research, Wen Xue, RNA Therapeutics Institute, Program in Molecular Medicine, Elinor Karlsson, Latest News, Xue Lab, Top Stories,
• 

  Apr 7, 2021

  Erik Sontheimer co-leading efforts to develop gene editing toolkit by NIH Somatic Cell Genome Editing Consortium

  Six UMass Medical School scientists are among the members of the National Institutes of Health’s Somatic Cell Genome Editing Consortium to publish a paper in Nature outlining the program’s goals.

  Read more

  , Graduate School of Biomedical Sciences, School of Medicine, Cancer Center, Watts Lab, Faculty, Rare Disease, Guangping Gao, Anastasia Khvorova, Jonathan K. Watts, Scot A. Wolfe, Wen Xue, Wolfe Lab, Sontheimer Lab, Molecular, Cell and Cancer Biology, RNA Therapeutics Institute, Li Weibo Institute for Rare Diseases Research, Gao Lab, Microbiology and Physiological Systems,